ImmunoPrecise Antibodies Ltd. (HYFT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ImmunoPrecise Antibodies Ltd. (HYFT) has a cash flow conversion efficiency ratio of -0.162x as of October 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.87 Million) by net assets ($17.70 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ImmunoPrecise Antibodies Ltd. (HYFT) liquidity interval to measure how many days the company can operate on defensive assets alone.
ImmunoPrecise Antibodies Ltd. - Cash Flow Conversion Efficiency Trend (1997–2025)
This chart illustrates how ImmunoPrecise Antibodies Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
ImmunoPrecise Antibodies Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ImmunoPrecise Antibodies Ltd. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tirupati Forge Limited
NSE:TIRUPATIFL
|
-0.024x |
|
Astra Exploration Inc
V:ASTR
|
-0.746x |
|
Korea Cable T.V Chung-Buk System Co. Ltd.
KQ:066790
|
-0.007x |
|
Infas Holding AG
F:IFS
|
-2.367x |
|
Redtone International Bhd
KLSE:0032
|
-0.013x |
|
Osteonic Co. Ltd
KQ:226400
|
0.017x |
|
Hankook Furniture Co. Ltd
KQ:004590
|
-0.025x |
|
Netbay Public Company Limited
BK:NETBAY
|
0.159x |
Annual Cash Flow Conversion Efficiency for ImmunoPrecise Antibodies Ltd. (1997–2025)
The table below shows the annual cash flow conversion efficiency of ImmunoPrecise Antibodies Ltd. from 1997 to 2025. For the full company profile with market capitalisation and key ratios, see HYFT market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-04-30 | $23.63 Million | $-6.41 Million | -0.271x | -116.75% |
| 2024-04-30 | $33.92 Million | $-4.25 Million | -0.125x | +63.52% |
| 2023-04-30 | $57.80 Million | $-19.83 Million | -0.343x | -159.84% |
| 2022-04-30 | $75.13 Million | $-9.92 Million | -0.132x | -1152.78% |
| 2021-04-30 | $56.92 Million | $-600.00K | -0.011x | +88.57% |
| 2020-04-30 | $15.09 Million | $-1.39 Million | -0.092x | +48.03% |
| 2019-04-30 | $18.07 Million | $-3.21 Million | -0.177x | +34.01% |
| 2018-04-30 | $12.70 Million | $-3.42 Million | -0.269x | -15.23% |
| 2017-04-30 | $3.09 Million | $-721.65K | -0.233x | -174.62% |
| 2016-04-30 | $908.26K | $284.09K | 0.313x | +80.64% |
| 2015-04-30 | $-208.52K | $-36.11K | 0.173x | -40.10% |
| 2014-04-30 | $-161.21K | $-46.60K | 0.289x | +1338.08% |
| 2013-04-30 | $-215.66K | $-4.33K | 0.020x | -98.18% |
| 2012-04-30 | $-119.89K | $-132.72K | 1.107x | +273.25% |
| 2011-04-30 | $125.81K | $-80.39K | -0.639x | -1011.31% |
| 2010-04-30 | $5.37 Million | $-308.49K | -0.057x | -150.56% |
| 2009-04-30 | $6.78 Million | $-155.68K | -0.023x | +77.54% |
| 2008-04-30 | $5.12 Million | $-523.45K | -0.102x | -85.67% |
| 2007-04-30 | $5.40 Million | $-297.31K | -0.055x | -94.49% |
| 2006-04-30 | $3.91 Million | $-110.59K | -0.028x | -45.53% |
| 2005-04-30 | $4.23 Million | $-82.20K | -0.019x | +84.83% |
| 2004-04-30 | $1.39 Million | $-178.69K | -0.128x | +30.59% |
| 2003-04-30 | $912.21K | $-168.38K | -0.185x | +54.45% |
| 2002-04-30 | $691.56K | $-280.23K | -0.405x | -1206.41% |
| 2001-04-30 | $262.24K | $-8.13K | -0.031x | +94.10% |
| 2000-04-30 | $396.53K | $-208.54K | -0.526x | -319.83% |
| 1999-04-30 | $1.62 Million | $-202.94K | -0.125x | -58.13% |
| 1998-04-30 | $2.86 Million | $-226.81K | -0.079x | -165.55% |
| 1997-04-30 | $3.63 Million | $-108.20K | -0.030x | -- |
About ImmunoPrecise Antibodies Ltd.
MindWalk Holdings Corp. operates as a bio-native AI company. It focuses on the integration of artificial intelligence, multi-omics data, and advanced laboratory research to accelerate the discovery and development of biologics. The company, through its LensAI platform and HYFT technology, it partners with pharmaceutical and biotechnology companies to drive de-risk drug development and unlock ther… Read more